| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
701.66(B) |
| Last
Volume: |
2,008,266 |
Avg
Vol: |
3,289,637 |
| 52
Week Range: |
$390.35 - $792.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
644,570 |
871,420 |
3,176,506 |
6,211,418 |
| Total Sell Value |
$465,524,857 |
$608,633,217 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
8 |
14 |
47 |
89 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dozier Eric |
EVP, HR & Diversity |
• – – |
2023-03-01 |
4 |
D |
$311.22 |
$222,211 |
D/D |
(714) |
6,808 |
|
- |
|
| Dozier Eric |
EVP, HR & Diversity |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,602 |
7,522 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-03-01 |
4 |
D |
$311.22 |
$246,797 |
D/D |
(793) |
9,908 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-03-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,779 |
10,701 |
|
- |
|
| Zakrowski Donald A |
SVP, Finance, & CAO |
• – – |
2023-02-27 |
4 |
AS |
$322.47 |
$193,482 |
D/D |
(600) |
6,578 |
|
43% |
|
| Greene Gabrielle E |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$4,913 |
D/D |
15 |
1,614 |
|
- |
|
| Fyrwald J Erik |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$9,825 |
D/D |
30 |
70,639 |
|
- |
|
| Johnson Kimberly H |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$9,825 |
D/D |
30 |
2,010 |
|
- |
|
| Hedley Mary Lynne |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$9,825 |
D/D |
30 |
623 |
|
- |
|
| Alvarez Ralph |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$11,463 |
D/D |
35 |
52,772 |
|
- |
|
| Luciano Juan R |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$14,410 |
D/D |
44 |
14,783 |
|
- |
|
| Tai Jackson P |
Director |
– • – |
2023-02-21 |
4 |
A |
$327.51 |
$1,965 |
D/D |
6 |
63,456 |
|
- |
|
| Norton Johna |
EVP, Global Quality |
• – – |
2023-02-17 |
4 |
GD |
$0.00 |
$0 |
D/D |
500 |
33,408 |
|
- |
|
| Van Naarden Jacob |
EVP and CEO Loxo@Lilly |
• – – |
2023-02-16 |
4 |
D |
$335.01 |
$440,203 |
D/D |
(1,314) |
11,845 |
|
- |
|
| Van Naarden Jacob |
EVP and CEO Loxo@Lilly |
• – – |
2023-02-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,785 |
13,159 |
|
- |
|
| White Anne E. |
EVP & Pres, Lilly Neuroscience |
• – – |
2023-02-13 |
4 |
AS |
$346.47 |
$866,175 |
D/D |
(2,500) |
57,926 |
|
31% |
|
| Hakim Anat |
EVP, GC & Secretary |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$3,130,929 |
D/D |
9,072 |
22,189 |
|
- |
|
| Dozier Eric |
EVP, HR & Diversity |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$628,118 |
D/D |
1,820 |
5,920 |
|
- |
|
| Skovronsky Daniel |
EVP, CS&MO & Pres., LRL |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$6,346,067 |
D/D |
18,388 |
105,587 |
|
- |
|
| Pusey Leigh Ann |
EVP, Corp. Affairs & Comm. |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$1,270,387 |
D/D |
3,681 |
31,641 |
|
- |
|
| White Anne E. |
EVP & Pres, Lilly Neuroscience |
• – – |
2023-02-10 |
4 |
AS |
$342.76 |
$856,900 |
D/D |
(2,500) |
60,426 |
|
33% |
|
| White Anne E. |
EVP & Pres, Lilly Neuroscience |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,954,917 |
D/D |
8,562 |
62,926 |
|
- |
|
| Weems Alonzo |
EVP, ERM & CECO |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$835,881 |
D/D |
2,422 |
8,922 |
|
- |
|
| Yuffa Ilya |
EVP & President, LLY Intl |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$465,912 |
D/D |
1,350 |
12,974 |
|
- |
|
| Mason Michael B |
EVP & Pres., Lilly Diabetes |
• – – |
2023-02-10 |
4 |
A |
$345.12 |
$2,768,898 |
D/D |
8,023 |
39,284 |
|
- |
|
1437 Records found
|
|
Page 8 of 58 |
|
|
8.64 (1.19%) 
